Monopar Stock Skyrockets After Agreement With AstraZeneca's Unit On Wilson's Disease Drug: Retail On Cloud Nine

Shares of Monopar Therapeutics, Inc. ($MNPR) soared over 500% on Thursday following a major licensing agreement with AstraZeneca ($AZN) unit Alexion. 

The stock hit its highest levels since March 2021 and became the top gainer across U.S. exchanges, with retail sentiment surging into ‘extremely bullish’ territory.

Monopar secured the rights to ALXN-1840, an oral treatment for Wilson’s disease, a rare genetic disorder that leads to toxic copper build-up in organs. 

The company will be responsible for all future global development and commercialization activities.

In exchange, Monopar will pay an upfront sum in cash and equity, along with future royalties and milestone payments. 

Under Alexion’s prior development, ALXN-1840 had already met its primary endpoint in a Phase 3 clinical trial.

On Stocktwits, retail sentiment for MNPR jumped to ‘extremely bullish’ (97/100), the highest score this year, driven by a surge in message volume as investors reacted to the breakthrough deal. 

Monpar stated that its MD, Co-Founder, and CEO, Chandler Robinson, previously conducted laboratory research on tetrathiomolybdate, published his findings in Science, and helped launch the company behind what became ALXN-1840. The focus was on Wilson disease.

Wilson’s disease affects around 1 in 30,000 people in the U.S., causing excess copper to accumulate in the liver, brain, and other organs. 

The disease can lead to liver failure, neurological symptoms, and psychiatric issues, with many cases suffering irreversible damage.

MNPR stock has now surged over 1,500% year-to-date.

For updates and corrections email newsroom@stocktwits.com

Read next: Air-Taxi Firm Lilium’s Stock Nosedives On Insolvency Warning: Retail Mood Darkens

Share

·

Add us on